{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:51:11Z","timestamp":1789080671014,"version":"build-2803163510"},"reference-count":27,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Spleen tyrosine kinase (SYK) and Bruton\u2019s tyrosine kinase (BTK) inhibitors have emerged as promising targeted therapies for adult immune thrombocytopenia (ITP). However, a comprehensive synthesis of their benefits compared to placebo has not been previously conducted. This study aims to analyze the efficacy and safety of SYK and BTK inhibitors in comparison to placebo for the treatment of adult patients with ITP. A systematic search was performed across four major databases (Medline, Europe PMC, Scopus, and ClinicalTrials.gov) for randomized controlled trials (RCTs) evaluating SYK and\/or BTK inhibitors versus placebo in adults with ITP. We utilized random-effects models to evaluate the risk ratio (RR) and mean difference (MD) for the occurrence of outcomes. Five RCTs across four publications were included. Both SYK and BTK inhibitors significantly improved overall platelet response (RR 3.95; 95%CI: 2.68 \u2013 5.81, p&lt;0.00001) and durable response rates (RR 12.50; 95%CI: 3.99 \u2013 39.18, p&lt;0.0001) compared to placebo. Treatment also resulted in shorter time to response and reduced need for rescue interventions. Although total AEs and rash were more common in the intervention group, these were predominantly grade 1\u20132 and did not lead to increased discontinuation or serious AE rates. No significant differences were observed in the specific events such as gastrointestinal symptoms, cytopenias, liver enzyme elevations, infections, or hypertension. SYK and BTK inhibitors demonstrate superior efficacy over placebo in improving platelet outcomes in adult ITP without compromising safety. These findings support their role as effective treatment options, especially for patients unresponsive to other therapies.<\/jats:p>","DOI":"10.46989\/001c.154588","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:48:16Z","timestamp":1766591296000},"source":"Crossref","is-referenced-by-count":1,"title":["Spleen and Bruton\u2019s tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.46989","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6795-7189","authenticated-orcid":false,"given":"Akhil D.","family":"Vatvani","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00dmrtm29","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, NYC Health + Hospitals\/Lincoln, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-9776","authenticated-orcid":true,"given":"Timotius I.","family":"Hariyanto","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, 15811, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9354-2494","authenticated-orcid":false,"given":"Alejandrina C.","family":"Ramirez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00dmrtm29","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, NYC Health + Hospitals\/Lincoln, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2480-6490","authenticated-orcid":false,"given":"Nehad","family":"Shabarek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00dmrtm29","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Internal Medicine, NYC Health + Hospitals\/Lincoln, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"A. Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"J. A. C. Sterne","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"ref3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"J. P. Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"X. Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"D. Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"ref6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"J. Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"11","author":"Y. Hu","year":"2024","journal-title":"Lancet Haematol"},{"issue":"24","key":"ref8","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"D. J. Kuter","year":"2025","journal-title":"Blood"},{"issue":"6","key":"ref9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"M. Kuwana","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"A. Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"N. Cooper","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"ref12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/sim.1461","article-title":"Adjusting for publication bias in the presence of heterogeneity","volume":"22","author":"N. Terrin","year":"2003","journal-title":"Stat Med"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"N. Cooper","year":"2023","journal-title":"Platelets"},{"issue":"19","key":"ref14","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"N. T. Connell","year":"2019","journal-title":"Blood"},{"issue":"24","key":"ref15","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2025028584","article-title":"Rilzabrutinib, the first-in-class BTK inhibitor for ITP","volume":"145","author":"M. Michel","year":"2025","journal-title":"Blood"},{"issue":"10","key":"ref16","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives","volume":"11","author":"E. Robak","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"ref17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/ajh.27303","article-title":"A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia","volume":"99","author":"S. Yan","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"ref18","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.27718","article-title":"Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia","volume":"100","author":"Q. S. Huang","year":"2025","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"ref19","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1002\/hem3.104","article-title":"Zanubrutinib and Eltrombopag as Second-Line Treatments for Patients With Immune Thrombocytopenia: An Open-Label, Randomized, Controlled, Phase 2 Trial","volume":"8","author":"C. Wang","year":"2024","journal-title":"EHA2024 Hybrid Congress. Hemasphere"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"X. G. Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"ref21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ajh.25092","article-title":"Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices","volume":"93","author":"A. Cuker","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"ref22","doi-asserted-by":"publisher","first-page":"C1231","DOI":"10.1152\/ajpcell.00040.2022","article-title":"Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology","volume":"323","author":"T. J. Zheng","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"issue":"S1","key":"ref23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5045\/br.2022.2022038","article-title":"Recent advances in treatments of adult immune thrombocytopenia","volume":"57","author":"D. S. Kim","year":"2022","journal-title":"Blood Res"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jox13010005","article-title":"Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials","volume":"13","author":"M. A. Ali","year":"2023","journal-title":"J Xenobiot"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5578929","DOI":"10.1155\/mi\/5578929","article-title":"Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence","volume":"2025","author":"A. Heidari","year":"2025","journal-title":"Mediators Inflamm"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"M. J. Page","year":"2021","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"20406207231205431","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"D. J. Kuter","year":"2023","journal-title":"Ther Adv Hematol"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/154588-spleen-and-bruton-s-tyrosine-kinase-inhibitors-for-the-management-of-adult-immune-thrombocytopenia-a-systematic-review-and-meta-analysis-of-randomize","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:48:17Z","timestamp":1766591297000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/154588-spleen-and-bruton-s-tyrosine-kinase-inhibitors-for-the-management-of-adult-immune-thrombocytopenia-a-systematic-review-and-meta-analysis-of-randomize"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.154588","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}